首页> 外文期刊>The journal of clinical psychiatry >Selectivity of Antidepressants: From the Monoamine Hypothesis of Depression to the SSRI Revolution and Beyond.
【24h】

Selectivity of Antidepressants: From the Monoamine Hypothesis of Depression to the SSRI Revolution and Beyond.

机译:抗抑郁药的选择性:从抑郁的单胺假说到SSRI革命及其后。

获取原文
获取原文并翻译 | 示例
           

摘要

In 2003, available pharmacotherapy for mood disorders was based almost entirely on observations from the 1950s and 1960s that agents that enhance monoamine transmitter function are effective antidepressants. Preclinical studies show that chronic administration of all effective antidepressants increases the efficiency of post-synaptic 5-HT transmission. Many antidepressants also modify nor-adrenergic function in the central nervous system. For the majority of antidepressants, these long-term changes in serotonergic and/or noradrenergic function result from direct antagonism of serotonin and/ or norepinephrine transporters (also termed "uptake sites"). Pharmacotherapy that is highly selective for one transporter over another has been demonstrated to be effective and tolerable, whereas agents that act on multiple transporters may not necessarily achieve better efficacy and may be associated with additional adverse events. Nevertheless, the rationale is in place to suggest that antidepressants that block both the serotonin and norepinephrine transporters might provide better efficacy, which can only be determined by empirical testing.
机译:2003年,可用于情绪障碍的药物疗法几乎完全基于1950年代和1960年代的观察结果,即增强单胺递质功能的药物是有效的抗抑郁药。临床前研究表明,长期服用所有有效的抗抑郁药可提高突触后5-HT传递的效率。许多抗抑郁药也会改变中枢神经系统的正肾上腺素功能。对于大多数抗抑郁药而言,血清素和/或去甲肾上腺素能功能的这些长期变化是由血清素和/或去甲肾上腺素转运蛋白(也称为“摄取位点”)的直接拮抗作用引起的。对一种转运蛋白具有高度选择性的药物治疗已被证明是有效且可耐受的,而作用于多种转运蛋白的药物不一定能达到更好的疗效,并且可能与其他不良事件有关。尽管如此,仍然有理由表明阻断5-羟色胺和去甲肾上腺素转运蛋白的抗抑郁药可能会提供更好的疗效,这只能通过经验测试来确定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号